Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis: A report of two cases

Authors

  • Masataka Kuwana MD,

    Corresponding author
    1. Division of Rheumatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    • Division of Rheumatology, Department of Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160, Japan
    Search for more papers by this author
  • Takao Fujii MD,

    1. Division of Rheumatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    Search for more papers by this author
  • Tsuneyo Mimori MD,

    1. Division of Rheumatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    Search for more papers by this author
  • Junichi Kaburaki MD

    1. Division of Rheumatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    Search for more papers by this author

Abstract

Anti-DNA topoisomerase I (anti–topo I) antibody profiles were compared before and after lung cancer in 2 patients with systemic sclerosis (SSc). Both patients developed adenocarcinoma of the lung late in the course of SSc and died of the cancer. Anti–topo I antibody levels, determined by double immunodiffusion and enzyme-linked immunosorbent assay, increased markedly at the time of diagnosis of lung cancer. Furthermore, patients' sera obtained after lung cancer reacted with multiple epitopes on the entire topo I molecule, some of which had not previously been recognized. These results further support the concept that anti–topo I antibody production in SSc patients is due to an antigen-driven process.

Ancillary